Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Tanabe/Taisho integrate operations

Executive Summary

Tanabe Seiyaku and Taisho Pharmaceutical will consolidate their pharmaceutical and OTC drug operations under a new holding company, to be headed by Tanabe President Toshio Tanaka. The move appears to take Tanabe out of the pool of potential pharmaceutical acquisition targets in Japan. The businesses will be integrated Oct. 1 and the holding company will be founded on April 1. Combined sales will be approximately $4 bil. in 2002

You may also be interested in...



Tanabe/Taisho terminate merger

Tanabe Seiyaku and Taisho Pharmaceutical terminate proposed merger, citing "differences regarding the most appropriate direction to be pursued post-merger," the companies said Dec. 3 ("The Pink Sheet" Sept. 24, In Brief)...

Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data

Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
UsernamePublicRestriction

Register

PS038558

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel